Načítá se...
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research st...
Uloženo v:
| Vydáno v: | Br J Cancer |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6325162/ https://ncbi.nlm.nih.gov/pubmed/30413824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0294-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|